A phase 3 randomized, double-blind, placebo- and active-controlled, multi-center, parallel group study to evaluate the safety and efficacy of darusentan in subjects with resistant hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic, as compared to guanfacine or placebo (protocol DAR-312).

Trial Profile

A phase 3 randomized, double-blind, placebo- and active-controlled, multi-center, parallel group study to evaluate the safety and efficacy of darusentan in subjects with resistant hypertension receiving combination therapy with three or more antihypertensive drugs, including a diuretic, as compared to guanfacine or placebo (protocol DAR-312).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2017

At a glance

  • Drugs Darusentan (Primary) ; Guanfacine
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms DORADO-AC
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Jul 2012 Additional locations added as reported by European Clinical Trials Database record.
    • 19 Mar 2010 Status of extension study changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from completed to discontinued as reported in Gilead's media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top